15th International Symposium MDS Copenhagen 2019:

Molecular characterization and clonal architecture of adult MDS/MPN.

Laura Palomo1,2, Manja Meggendorfer1, Stephan Hutter1, Sven Twardziok1, Vera Ademà1,3, Irene Fuhrmann1, Francisco Fuster-tormo2, Pamela Acha2, Francesc Solé2, Claudia Haferlach1, Torsten Haferlach.

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes.

Elsa Bernard, Phd1*, Yasuhito Nannya, Md, Phd2, Tetsuichi Yoshizato, Md, Phd3, Robert P. Hasserjian, Md4, Ryunosuke Saiki5*, Yusuke Shiozawa, Md, Phd6*, Sean M. Devlin, Phd7*, Heinz Tuechler8*, Araxe Sarian1*, Luca Malcovati, Md9, Francesc Sole, Phd10, Detlef Haase, Md11*, Maria Creignou12*, Max Levine, Ms13*, Ulrich Germing, Md14*, Catherine Cargo, Mb, Frcpath15*, Yanming Zhang, Md16, Juan Medina, Ms17*, Juan E. Arango Ossa, Bs1*, Julie Schanz, Md, Phd11*, Arjan Van De Loosdrecht, Md, Phd18*, Martin Jädersten, Md, Phd19*, John M. Bennett, Md20, Magnus Tobiasson, Md, Phd21*, Olivier Kosmider, Pharmd, Phd22*, Matilde Y Follo, Phd23*, Felicitas Thol, Md24, Ronald F Pinheiro, Md25*, Valeria Santini, Md26, Ioannis Kotsianidis27*, Jacqueline Boultwood28, Fabio Ps Santos, Md29, Senji Kasahara, Md, Phd30, Takayuki Ishikawa, Md, Phd31, Hisashi Tsurumi, Md, Phd32, Akifumi Takaori-kondo, Md, Phd33, Toru Kiguchi34*, Chantana Polprasert, Md35*, Virginia M. Klimek, Md36, Michael R. Savona, Md37, Monika Belickova, Phd38*, Christina Ganster11, Lionel Ades, Md, Phd39, Matteo Giovanni Della Porta, Md40*, Alexandra Smith, Phd41*, Yesenia Werner1*, Minal A Patel, Mph42*, Agnes Viale, Phd1*, Katelynd Vanness1*, Donna S Neuberg, Scd43, Kristen E. Stevenson, Ms44*, Kamal Menghrajani, Md36, Kelly L Bolton, Md, Phd45, Pierre Fenaux, Md, Phd46, Andrea Pellagatti28*, Uwe Platzbecker, Md47, Michael Heuser, Md48, Peter Valent, Md49, Shigeru Chiba, Md, Phd50*, Yasushi Miyazaki, Md, Phd51, Carlo Finelli52*, Maria Teresa Voso, Md53, Lee-yung Shih, Md54, Michaela Fontenay, Md, Phd55, Joop H. Jansen, Phd56, José Cervera, Md, Phd57*, Yoshiko Atsuta, Md, Phd58*, Norbert Gattermann, Md59, Benjamin L. Ebert, Md, Phd60, Rafael Bejar, Md, Phd61, Peter L Greenberg, Md62, Mario Cazzola, Md63, Eva Hellstrom Lindberg, Md, Phd64, Seishi Ogawa, Md, Phd3 And Elli Papaemmanuil, Phd65.

Long-term Benefits After Discontinuation Of Lenalidomide Due To Adverse Events In Patients With Del (5q) Myelodysplastic Syndromes.

F. Hernandez Mohedo1, C. Alarcon Payer2, E. Mora Casterá3, S. Romero Dominguez3, B. López Andrade4, A.R. González5, G. Sanz3.

Clinical And Mutational Profiles Differentiate Hypoplastic From Hyperplastic Myelodysplastic Syndrome And Myelodysplastic Syndrome With Isolated Deletion Of 5q.

F. Hernandez Mohedo1, F. Solé Ristol2, M. Bernal Sánchez1, L. Palomo Sanchís2, M. Jurado Chacón1.

60th ASH Annual Meeting 2019:

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

David P. Steensma1, Martin Wermke2, Virginia M. Klimek3, Peter L Greenberg4, Patricia Font5, Rami S. Komrokji6, Jay Yang7, Andrew M. Brunner8, Hetty E. Carraway9, Lionel Ades10, Aref Al-Kali11, Juan Manuel Alonso Dominguez12, Ana Alonso13, Catherine C. Coombs14, H. Joachim Deeg15, William B. Donnellan16, James M. Foran17, Guillermo Garcia-Manero18, Michael B. Maris19, Malgorzata McMasters20, Jean-Baptiste Micol21, Jaime Perez De Oteyza22, Felicitas Thol23, Eunice S. Wang24, Justin M. Watts25, Silvia Buonamici26, Amy Kim26, Vikram Gourineni26, Alyssa J Marino26, Nathalie Rioux26, Joanne Schindler26, Sherri Smith26, Huilan Yao26, Xiaobin Yuan27, Kun Yu26, Uwe Platzbecker28.